Bailard Inc. Makes New $106,000 Investment in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Bailard Inc. bought a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 19,720 shares of the medical instruments supplier’s stock, valued at approximately $106,000.

A number of other large investors also recently made changes to their positions in the business. Strs Ohio grew its position in Harvard Bioscience by 37.0% during the third quarter. Strs Ohio now owns 125,400 shares of the medical instruments supplier’s stock valued at $539,000 after purchasing an additional 33,900 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Harvard Bioscience by 1.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 227,002 shares of the medical instruments supplier’s stock valued at $976,000 after acquiring an additional 2,758 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Harvard Bioscience by 64.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 161,819 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 63,174 shares during the last quarter. Acuitas Investments LLC raised its holdings in shares of Harvard Bioscience by 34.1% during the third quarter. Acuitas Investments LLC now owns 241,781 shares of the medical instruments supplier’s stock worth $1,040,000 after acquiring an additional 61,481 shares in the last quarter. Finally, Punch & Associates Investment Management Inc. boosted its position in Harvard Bioscience by 2.1% during the third quarter. Punch & Associates Investment Management Inc. now owns 2,923,034 shares of the medical instruments supplier’s stock valued at $12,569,000 after purchasing an additional 60,385 shares during the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Stock Performance

Shares of NASDAQ HBIO opened at $3.71 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.92 and a current ratio of 1.85. Harvard Bioscience, Inc. has a one year low of $3.44 and a one year high of $6.29. The business’s 50-day moving average price is $4.21 and its two-hundred day moving average price is $4.47.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%. The firm had revenue of $28.15 million for the quarter, compared to analyst estimates of $27.80 million. Sell-side analysts anticipate that Harvard Bioscience, Inc. will post 0.14 earnings per share for the current year.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.